N=nitrogen *Both regimens have added trace elementsand fat and water soluble vitamins mixture had a total osmolality of 490 mosmollkg and provided 10 g nitrogen and 1400 non-protein kcal (5.9 MJ) over 24 h (Table 1) . Regimen B consisted of 1000 ml Yamin 9 Glucose" (KabiVitrum Ltd, UK), 1000 ml Dextrose 10% (Travenol Laboratories Ltd, UK), and 1000 ml Dextrose 10% (Travenol Laboratories Ltd, UK), and 1000 ml Intralipid 10%@ (KabiVitrum Ltd, UK). It had an osmolality of 720 mosmollkg and delivered 9.4 g nitrogen and 1900 non-protein kcal (8.0 MJ) daily (Table 1 ). Both regimens had added electrolytes, trace elements, and water-and fat-soluble vitamins. Daily regimens, provided in 3-litre bags, were infused over 24 h by metered volumetric pumps (Imed 927@). Within each regimen, the patients were randomized to receive a self-adhesive patch of either Transiderm-Nitro 5@ (Ciba-Geigy Pharmaceuticals) which releases 5 mg of GTN daily at a continuous rate, or an identical placebo. The patches were applied immediately after venous cannulation, distal and as close as possible to the cannulation site and replaced daily. For cannulae sited on the dorsum of the hand, the patches were placed alongside the cannulae.
The same make of delivery systems (KabiVitrum Ltd, UK) and 18 G Teflon cannulae (Venflon@ 2, Viggo AB) were inserted by a team of five junior surgeons according to standard procedures for skin preparation, cannula insertion, and care of intravenous sites". Only one infusion site was studied per patient in an upper limb which had not been used for any form of intravenous therapy in the previous 2 weeks. The 
Introduction
Total parenteral nutrition (TPN) via peripheral veins is appealing, but vein tolerance remains a major problem. It has been suggested that infusion phlebitis is initiated by venoconstriction at the infusion site', hence treatment with a vasodilator may reduce its incidence. We have tested this hypothesis and reported that the use of transdermal glyceryl trinitrate (GTN) reduced the failure rate of peripheral intravenous infusions''. This finding, coupled with the availability of high-calorie containing iso-osmolar lipid solutions has raised the possibility of infusing parenteral feeding regimens via peripheral veins.
Patients, materials and methods All patients between 16 and 80 years of age requiring parenteral nutrition were considered. Patients with renal function impairment, glaucoma and/or an unstable cardiovascular system, those receiving antiinflammatory or vasodilator drugs and those who were known to be allergic to GTN or Elastoplast were not entered in the study. All patients gave written informed consent.
Seventy-two consecutive patients were randomly allocated to two regimens. Regimen A consisted of 2000 ml of Perifusinw (E Merck Ltd, UK), 500 ml dextrose 20% (Travenol Laboratories Ltd, UK) and 500 ml Intralipid 20%@ (Kabivitrum Ltd, UK). This Summary Seventy-two consecutive patients reqmrmg total parenteral nutrition (TPN) were randomized to two groups. Group A received daily a peripheral intravenous regimen which provided 10 g nitrogen and 1400 non-nitrogen kcal (5.9 MJ). Group B received daily a peripheral intravenous regimen which delivered 9.4 g nitrogen and 1900 non-nitrogen kcal (8.0 MJ). Each group was further randomized to receive a selfadhesive patch of transdermal glyceryl trinitrate (GTN) or an identical placebo. Infusion survival was the main end-point. For group A, the median time of infusion survival was 74 h (range: 58-100) in the control group compared with 108 h (range: 68-156) in the group that received transdermal GTN (P< 0.001). For group B, the median infusion survival was 67 h (range: 46-92) in the control group compared with 103 h (range: 66-151) in the treatment group (P< 0.001). TPN is feasible via peripheral veins and the incidence of infusion failure can be effectively reduced by transdermal GTN. More than one III 0/1 reason* Accidental removal 0/0 Oil *A combination of phlebitis, extravasation and/or irregular drip rate infusion groups were studied simultaneously to avoid a possible time-related effect.
The infusion was discontinued and the cannula removed when it was no longer required for treatment or when it failed. Failure of infusion was defined as the occurrence of phlebitis, extravasation or an irregular drip rate. Phlebitis was defined as the presence of two or more of the following signs: pain, erythema, swelling, excessive warmth, or a palpable venous cord.
Venepuncture sites were inspected by the same investigator, together with a trained nurse, 12 hourly or when an irregularity of drip rate or the patient's discomfort were reported. Routine haematological and biochemical monitoring for patients receiving TPN was carried out in all cases. Data and adverse effects were recorded on a standard form for each patient.
Incidence of infusion failure was analysed by lifetable methods. In particular, cannula survival was estimated using the method of Kaplan and Meier" and between group comparisons were made using the log rank test", Cox's proportional hazard techniques was used to assess the independent association of treatment and regimen with cannula survival, adjusting for confounding effects of age, sex, site of cannulation and insertor.
Results
The treatment and control groups in each infusion regimen were comparable for age, sex, and site of cannulation. The non-dominant limb was used more frequently than the dominant one with the forearm being the commonest site of cannulation (Table 2 ). Furthermore, there were no significant between-group differences in the reasons for removing the cannulae, (Figure 2 ; log rank X 2 =32.5, P<O.OOl). This significantly increased cannula survival, associated with the treatment group, is apparent for both infusion regimens. Combining the data from both regimens, we obtain estimated 96-h cannula survival rate of 5.9% and 82.4% for the control and treatment groups respectively (difference =76.5%, 95% confidence interval (Cl) for difference from 61.4% to 91.5%). A 95% CI for the proportion of cannulae surviving in the treatment group at 96 h is 69.5% to 95.2%. Comparison of the control groups in infusion regimens A and B showed that cannula survival was greater in regimen A (log rank X 2=4.7, df=l, P=0.031). However, there was no significant difference in cannula survival between the treatment groups in both infusion regimens (log rank x 2 = 0.3, df=l, P=0.593).
Differences in infusion survival between control and treatment groups, within each regimen, remained significant when allowance was made for differences between the five doctors who inserted the cannulae, age and sex of patients, and cannulae site using Cox's proportional hazard technique (relative risk offailure in the treatment group=0.0039, 95% CI 0.0009 to 0.0162).
Headache and skin rash were the only side effects noted and showed no between group difference <Table 4). One patient had a subcutaneous haematoma at the site of cannulation, and venous cannulation, in two Table 4 . Adverse reactions patients, was not achieved after two venepuncture attempts. However, all three patients went on to have successful cannulation in the other upper limb. There was no clinical evidence of catheter sepsis, and none of the patients had significant changes in their blood haematology and biochemistry over the study period.
Discussion
The above results demonstrate the feasibility ofTPN via peripheral veins, and confirm the previous reports that transdermal GTN reduces the incidence of peripheral intravenous infusion failure-",
The aetiology of infusion phlebitis is multifactorial". Duration and site of infusion, rate of flow, nature ofinfusate and drug additives including the pH and particulate matter, size of vein, cannula size and material, trauma at venepuncture and infection have all been incriminated. Several regimens have been suggested for prophylaxis including in-line filtration, neutralization of acid solutions and the addition of steroids and/or heparin to the infusate. However, these prophylactic measures have their limitations and have not gained wide approval.
In clinical practice, hyperosmolar solutions and irritant drugs are usually given via central rather than peripheral veins because the greater blood flow in central veins rapidly dilutes the infusate. Thus, the concept of increasing the blood flow in peripheral veins is appealing and may reduce the incidence of infusion phlebitis. Transdermal GTN has been shown to induce local vasodilatation's", and sublingual GTN has been reported to increase blood flow whilst decreasing vascular resistance and venous tone in the forearm!". The drug has also been shown to stimulate synthesis of prostacyclin by cultured human endothelial cells ll . Prostacyclin relaxes smooth muscle cells in vein walls and is also a potent inhibitor of platelet aggregation. The maintenance of an effective concentration of prostacyclin at infusion sites may prevent venoconstriction and platelet aggregation; thereby possibly reducing the incidence of infusion phlebitis.
Another contributory factor enabling peripheral TPN may be the use offat emulsions. Intralipid'"(KabiVitrum Ltd, UK) contributed 71% and 58% of the nonnitrogen energy in regimens A and B respectively. It has been reported that the addition of Intralipids' to a glucose solution buffers the vein wall and reduces endothelial inj ury12,13 . Furthermore, a number of irritant drugs are now made up in lipid media, with great improvement in vein tolerance (eg diazepam as diazemulsv'", and etomidate-P).
The populations in the treatment and control groups were comparable in terms of age, sex, and site of cannulation.
The incidence of headaches and skin rashes were similar in the control and treatment groups. The
Regimen A Regimen B Control!Treatment Control!Treatment
incidence of headache in patients receiving TPN has not been reported and it may be greater than in the normal population. However, the incidence of headache in the treatment group (11.1% in regimen A; 5.5% in regimen B) is not different from that reported previously'-", In all cases, the headache responded to analgesia and the patients opted to carry on with the trial. Only one patient in the control group of regimen A had a skin rash which is, therefore, likely to be due to the adhesive part of the patch.
Blackburn et al. 16 advocated the use of isotonic amino acids for peripheral intravenous feeding. Since then, many workers have investigated the metabolic effects of exogenous energy substrates, and have concluded that isotonic amino acids alone have no significant protein-sparing effect 17 ,18 and that an ideal regimen should provide amino acids, fat and glucose together with electrolytes, trace elements and vitamins'<!". However, the hypertonicity of such mixtures has compelled clinicians to use central rather than peripheral veins in order to avoid peripheral venous phlebitis. Central venous cannulation requires skill and may be time consuming. In our institution, we site all central venous feeding lines under strict sterile conditions in the operating room. The complications of such technique are well documented-", Therefore, the use of parenteral feeding regimens employing a simpler, safer, and cheaper method of venous access is appealing, but has until recently not been considered practicable.
There have been a few reports of peripheral intravenous administration ofTPNregimens. The use of hyperosmolar solutions necessitated frequent change of the infusion site due to' phlebitis'", Addition of heparin (1 Il.I/ml), hydrocortisone (5 mgt ml) or heparin (1 Il.I/ml) and hydrocortisone (5 mg/l), and sodium hydroxide as a buffer (1.8 mEqll) to the infusate resulted in improved vein tolerance'<. The reasons why these measures didn't gain wide approval require further investigations. Furthermore, there is evidence that the addition of heparin to the infusate may result in creaming of lipid emulsions due to the formation of calcium-heparin-lipid cornplex-", The non-protein calories in the regimens used in this study were relatively low. Elwyn 24 and Macfie'" have shown that estimations of calorie requirements have been excessive in the past and their work suggests that the energy inputs in our study are adequate to meet the needs of many postoperative patients. We did not carry out metabolic studies. However, our patients remained clinically well and biochemically stable throughout the study period.
Wilson et al. 26 have reported good metabolic profiles in :LO patients who were intravenously fed with a regimen similar to regimen A. Furthermore, it is now well accepted that fat is a beneficial energy source. We have recently reported good utilization of intravenous lipid emulsions, when given as 50% of non-nitrogen energy, with good intravascular lipolysis, presumably due to activation of intravascular lipoprotein lipase'".
The cannulae survived longer than 4 days in the majority of patients who received transdermal GTN, thus obviating the need for frequent changes of the cannulation site. This fact, coupled with the early recovery of the infusion site, has relevance both to the comfort of the patient and to the convenience of medical and nursing staff. 
Headache Skin rash
We are not advocating that peripheral TPN should replace central venous total parenteral nutrition in the hypercatabolic patients where the energy requirements are great, or in those patients requiring parenteral nutritional support for a long time. However, there are a number of patients in whom intravenous nutrition is indicated, but central venous cannulation is not desirable. Such patients include those who demonstrate signs of venous thrombosis, those who need preservation of central lines for other clinical reasons, those with complications necessitating removal of the central line, and those who have commenced enteral feeding but in whom the degree of absorption is not established. A prospective survey in our hospital of 248 consecutive patients who received central venous nutrition showed that only 42 patients (17%) required feeding for longer than 10 days (personal data). Therefore, we now use peripheral nutrition as a holding regimen pending reappraisal of nutritional needs. This avoids complications of central venous cannulation, simplifies nursing care, reduces costs and may prevent delay in initiating nutritional support. Furthermore, this route of delivery of nutrients was widely accepted by the nursing staff and patients alike.
We believe that peripheral TPN is a safe alternative to central venous feeding for most patients requiring short term intravenous nutrition and should be considered when planning nutritional therapy. The use of transdermal GTN makes such an alternative feasible by improving vein tolerance. This technique of peripheral intravenous feeding is certainly superior to central venous TPN in terms of risks and complications. Whether or not it will prove metabolically adequate awaits further investigations.
